Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE‐AF
暂无分享,去创建一个
D. McManus | J. Gurwitz | J. Saczynski | R. Goldberg | Tanya Mailhot | C. Kiefe | D. Lessard | Robert H. Helm | M. Waring | Francesca Marino | D. Parish | Bruce Barton | F. Sogade | Benita A. Bamgbade | Saket R. Sanghai | Weijia Wang | B. Bamgbade
[1] L. Allen,et al. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation , 2019, American heart journal.
[2] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.
[3] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.
[4] J. Díez-Manglano,et al. Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation , 2018, Internal and Emergency Medicine.
[5] M. Turakhia,et al. Predictors of oral anticoagulant non‐prescription in patients with atrial fibrillation and elevated stroke risk , 2018, American heart journal.
[6] B. Gersh,et al. Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community‐Based Cohort of Atrial Fibrillation , 2018, Mayo Clinic proceedings.
[7] R. Romero-Ortuño,et al. Clinical frailty is independently associated with non‐prescription of anticoagulants in older patients with atrial fibrillation , 2017, Geriatrics & gerontology international.
[8] G. Aksan,et al. Real‐World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl‐life Multicenter Survey Evaluating Stroke Study , 2017, Journal of the American Geriatrics Society.
[9] D. Singer,et al. Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke , 2017, Journal of the American Geriatrics Society.
[10] C. Tannenbaum,et al. The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. , 2016, The Canadian journal of cardiology.
[11] R. Cumming,et al. Atrial fibrillation in older inpatients: are there any differences in clinical characteristics and pharmacological treatment between the frail and the non‐frail? , 2016, Internal medicine journal.
[12] L. Ngo,et al. The Montreal Cognitive Assessment: Creating a Crosswalk with the Mini‐Mental State Examination , 2015, Journal of the American Geriatrics Society.
[13] F. Puisieux,et al. Underuse of Oral Anticoagulation for Individuals with Atrial Fibrillation in a Nursing Home Setting in France: Comparisons of Resident Characteristics and Physician Attitude , 2015, Journal of the American Geriatrics Society.
[14] F. Maes,et al. Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation? , 2014, Clinical interventions in aging.
[15] D. Singer,et al. Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2014, Circulation.
[16] Donald R. Miller,et al. Outcomes of Anticoagulation Therapy in Patients with Mental Health Conditions , 2014, Journal of General Internal Medicine.
[17] D. Singer,et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. , 2013, The American journal of cardiology.
[18] D. Alsop,et al. Novel risk markers and long-term outcomes of delirium: the successful aging after elective surgery (SAGES) study design and methods. , 2012, Journal of the American Medical Directors Association.
[19] G. Lip,et al. Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation , 2012, Circulation.
[20] J. Cornuz,et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. , 2012, The American journal of medicine.
[21] Stanley Nattel,et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.
[22] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[23] John Spertus,et al. Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.
[24] G. Lip,et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. , 2010, The American journal of medicine.
[25] B. Horne,et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. , 2010, Heart rhythm.
[26] M. Boustani,et al. Impact and recognition of cognitive impairment among hospitalized elders. , 2010, Journal of hospital medicine.
[27] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[28] C. Blaum,et al. Comparing Models of Frailty: The Health and Retirement Study , 2009, Journal of the American Geriatrics Society.
[29] S. Matthews,et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. , 2008, Age and ageing.
[30] A. Localio,et al. Risk factors for nonadherence to warfarin: results from the IN‐RANGE study , 2008, Pharmacoepidemiology and drug safety.
[31] G. Lip,et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.
[32] R. Spitzer,et al. The PHQ-9 , 2001, Journal of General Internal Medicine.
[33] S. Black,et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards , 2006, Stroke.
[34] J. Cummings,et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.
[35] T. Egberts,et al. Cognitive Impairment as Determinant for Sub-Optimal Control of Oral Anticoagulation Treatment in Elderly Patients with Atrial Fibrillation , 2005, Drugs & aging.
[36] D. Leys,et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. , 2004, British journal of clinical pharmacology.
[37] L. Fried,et al. Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.
[38] O. Benavente,et al. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.
[39] C. Sherbourne,et al. The MOS social support survey. , 1991, Social science & medicine.